Physician profile
Thomas Lingen
NPI 1003842402
$396.13
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $81.34 · 2021: $124 · 2022: $53.27.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.02 | 2019-2022 | |
| Novo Nordisk INC | $53.93 | 2019-2021 | |
| Amgen INC. | $41.13 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $37.37 | 2019-2022 | |
| Astellas Pharma US INC | $30.91 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $26.29 | 2020-2022 | |
| Lilly USA, LLC | $26.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.67 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.16 | 2021 | |
| Pfizer INC. | $12.47 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lingen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.